{"id":"NCT00887679","sponsor":"Duke University","briefTitle":"Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS","officialTitle":"Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder, Adherence to Antiretroviral Therapy,Cognition, and Immune Status Among Patients With HIV and AIDS: A 6-week Open-label, Prospective, Pilot Trial.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2009-09","completion":"2010-09","firstPosted":"2009-04-24","resultsPosted":"2014-03-10","lastUpdate":"2014-10-31"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anxiety Disorders","HIV Infections"],"interventions":[{"type":"DRUG","name":"Escitalopram","otherNames":[]}],"arms":[{"label":"Escitalopram","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate whether escitalopram is safe, well tolerated, and effective in the treatment of HIV-infected patients with generalized anxiety disorder.","primaryOutcome":{"measure":"Change From Randomization to End of Treatment in Scores on the Hamilton Anxiety Rating Scale (HAM-A)","timeFrame":"baseline and 7 weeks","effectByArm":[{"arm":"Escitalopram","deltaMin":21.23,"sd":2.57}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["16639343","14534388"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["nause","dizziness","dry mouth","diarrhea","constipation"]}}